Viking Therapeutics, Inc. · NASDAQ:VKTX

Viking Therapeutics — ObesityWeek 2026

47 slides from Viking Therapeutics's conference presentation, Nov 15, 2026

  1. Slide 1: ObesityWeek 2026

    ObesityWeek 2026

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward - looking stateme nts for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ mat erially

  3. Slide 3: Advancing Blockbuster Metabolic Pipeline and Preparing for Obesity Commercialization

    Viking Therapeutics: Advancing Blockbuster Metabolic Pipeline and Preparing for Obesity Commercialization • Dual agonist of GLP - 1 and GIP receptors for obesity Lead VK2735 Well-Positioned • Currently in VANQUISH Phase 3 trials in a Blockbuster Market • Potentially 3rd obesity franchise to market O

  4. Slide 4: Advancing Metabolic Pipeline in Obesity and Beyond

    Advancing Metabolic Pipeline in Obesity and Beyond Development Programs PRECLIN PHASE 1 PHASE 2 PHASE 3 Phase 3 VANQUISH trial ongoing; VK2735 Subcutaneous Obesity Phase 1 maintenance study Dual GLP - 1/GIP agonist completed VK2735 Oral Obesity Phase 3 SUNRISE trials underway; Dual GLP - 1/GIP agoni

  5. Slide 5: Obesity Market: Vast and Rapidly Expanding to Address Related Comorbidities

    Obesity Market: Vast and Rapidly Expanding to Address Related Comorbidities 1 Billion+ 200+ Adults living with obesity globally; Comorbidities, including: prevalence growing across markets • Cardiovascular disease • Hypertension • Type 2 diabetes • Dyslipidemia • Fatty liver disease • Chronic kidney

  6. Slide 6: Opportunity for VK2735 to Capture Significant Share Across Growing Obesity Market

    Opportunity for VK2735 to Capture Significant Share Across Growing Obesity Market in Both Oral and SC Formulations Obesity Market $150B+ Avg. Mkt Share Based on Order of Market Entry3 Projections (16% CAGR) (10yr Post - Launch) Revenue potential: $60B 40% 1st to Market $50B 33% 2nd to Market $29B 19

  7. Slide 7: VK2735 Subcutaneous Formulation Obesity

    VK2735 Subcutaneous Formulation Obesity 7

  8. Slide 8: History of Viking VK2735 Obesity Program

    History of Viking VK2735 Obesity Program VK2735 maintenance dosing study completed VK2735 VANQUISH Phase 3 studies initiated; now fully VK2735 VK2735 enrolled SUNRISE Oral VENTURE Phase Phase 3 studies 2 subcutaneous initiated study completed VK2735 VENTURE VK2735 Injectable Phase 1 SAD/MAD Phase 2

  9. Slide 9: VK2735 Shows Positive Results in Head-to-Head Study in Primates vs. Tirzepatide

    VK2735 Shows Positive Results in Head-to-Head Study in Primates vs. Tirzepatide • PK profile demonstrates higher Cmax, later Tmax, longer T1/2 vs. tirzepatide • Differences lead to increased exposures over time Mean Plasma Concentration – Single Dose Mean Plasma Concentration - Week 8 2000 4000 VK27

  10. Slide 10: VK2735 Induces Rapid Weight Loss in Obese Primate

    VK2735 Induces Mean Weight Change at 8 Weeks Rapid Weight Loss in (Change from baseline, %) Obese Primate Vehicle (n=12) Tirzepatide (n=12) VK2735 (n=12) Model vs Tirzepitide 2 +3.3% *** *** • Significant, progressive body 0 weight reduction observed over 8 -2 weeks -4 -6.5% • ~40%+ improvement in w

  11. Slide 11: VK2735 Subcutaneous Data Demonstrates Rapid, Progressive Weight Loss with Favorable Tolerability

    VK2735 Subcutaneous Data Demonstrates Rapid, Progressive Weight Loss with Favorable Tolerability Profile Subcutaneous Phase 1 SAD Study Subcutaneous Phase 1 MAD Study Predictable after 28 days in -7.8% Dose-dependent Key Takeaways Well-tolerated weight loss up to subjects with pharmacokinetics BMI ≥

  12. Slide 12: VENTURE Phase 2 Study Achieved Primary Endpoint

    VENTURE Phase 2 Study Mean Change in Body Weight After 13 Weeks Achieved Primary Endpoint Change from baseline (%) VK2735 VK2735 VK2735 VK2735 Placebo 2.5 mg 5.0 mg 10.0 mg 15.0 mg (n=34) (n=35) (n=35) (n=35) (n=35) • Significant reduction in 0 -1.7% body weight observed after 13 weeks -3 • Up to ap

  13. Slide 13: VENTURE Phase 2 Results: Rapid, Progressive Weight Loss Observed

    VENTURE Phase 2 Results: Rapid, Progressive Weight Loss Observed Body Weight Percent Change from Baseline over 13 Weeks (LSM±SE) • Progressive weight loss observed in all VK2735 dosing cohorts • All doses statistically significant vs. placebo starting in Week 1 and maintained through Week 13 • Dose-

  14. Slide 14: VENTURE Phase 2 Results: Rapid, Progressive Weight Loss Observed

    VENTURE Phase 2 Results: Rapid, Progressive Weight Loss Observed Week 12 Plasma Concentration by Treatment Group and Dose • Plasma levels remain in therapeutic Semi-logarithmic Scale range 30 days following last dose 10000 30 days • Suggestive of less frequent administration providing benefit 1000 M

  15. Slide 15: VK2735-102 Maintenance Study

    VK2735-102 Maintenance Study 15

  16. Slide 16: Expanding on VK2735 Holistic Weight Loss Potential

    Expanding on VK2735 Holistic Weight Loss Potential VK2735 SC VK2735 SC VK2735 Oral Maintenance Phase 2 data presented 2/27/2024 Phase 2 data presented 8/19/2025 Preliminary maintenance data • Up to 14.7% body weight reduction • Up to 12.2% body weight reduction • Potential to unlock new platform aft

  17. Slide 17: VK2735-102: Maintenance Study Design

    VK2735-102: Maintenance Study Design Part 1: Subcutaneous (SC) maintenance dosing • Designed to evaluate transition from Weekly (QW) to SC monthly (QM) or every other week (QOW) dosing regimens • Endpoints: Safety, tolerability, PK, weight change 1.25 2.5 mg mg 5.0 mg 7.5 mg 10.0 mg 12.5 mg 15.0 mg

  18. Slide 18: VK2735-102 Maintenance Study: Key Questions

    VK2735-102 Maintenance Study: Key Questions Efficacy Tolerability Trajectory • Based on prior Phase 2 weight • Does rapid titration reduce • How does weekly dosing curve loss and PK data: tolerability? look at W21 and W33? • Does every-other-week dosing • Does less frequent dosing lead to • Lack of

  19. Slide 19: Maintenance Study: Induction Weight Loss Through Week 21

    Maintenance Study: Induction Weight Loss Through Week 21 Body Weight Percent Change from Baseline over 21 Weeks (LSM±SE) • Significant and progressive reduction in body weight observed after 21 weeks in all VK2735 cohorts • Up to approximately 19% weight loss from baseline • 17.8% weight loss from b

  20. Slide 20: High Proportion of VK2735 Participants Achieve Key Weight Loss Thresholds at Week 21

    High Proportion of VK2735 Participants Achieve Key Weight Loss Thresholds at Week 21 5% Weight Loss 10% Weight Loss 15% Weight Loss 20% Weight Loss VK2735, Combined 1 98% 90% 65% 32% n=143 Placebo 13% 0% 0% 0% n=15 p-value vs. placebo <0.0001 <0.0001 <0.0001 <0.01 Notes: 1) Observed values for subje

  21. Slide 21: Maintenance of Weight Loss with Every-Other-Week Dosing

    Maintenance Study: Maintenance of Weight Loss with Every- Other-Week Dosing Percent of Weight Loss Maintained from W21 to W33 (LSM±SE) • Up to approximately 97% maintenance of weight loss observed following transition to every-other-week dosing • Compares favorably to 61% maintenance effect for part

  22. Slide 22: Maintenance of Weight Loss with Monthly Dosing

    Maintenance Study: Maintenance of Weight Loss with Monthly Dosing Percent of Weight Loss Maintained from W21 to W33 (LSM±SE) • Up to approximately 90% maintenance of weight loss observed following transition to monthly dosing • Compares favorably to 61% maintenance effect for participants transition

  23. Slide 23: 17.5 mg Weekly Dosing Provides Highly Competitive 22% Weight Loss at W33

    Maintenance Study: 17.5 mg Weekly Dosing Provides Highly Competitive 22% Weight Loss at W33 Body Weight Percent Change from Baseline over 33 Weeks (LSM±SE) • Continued weekly dosing at 17.5 mg leads to progressive weight loss of up to approximately 22% • No plateau observed, suggesting continued wei

  24. Slide 24: Broad Improvement in Lipids Following Weekly Dosing

    Broad Improvement in Lipids Following 21 Weeks of Weekly Dosing Percent Change from Baseline at 22 Weeks (LSM±SE) • Encouraging lipid Placebo 15 mg 17.5 mg 20 mg 22.5 mg Total Active reductions following 21 15 (N=15) (N=14) (N=119) (N=15) (N=15) (N=163) weeks of treatment +9.3 5 • Observed reduction

  25. Slide 25: Sustained Improvement in Lipids Following Every-Other-Week Maintenance Dosing

    Sustained Improvement in Lipids Following 12 Weeks of Every- Other-Week Maintenance Dosing Percent Change from Baseline at 34 Weeks (LSM±SE) • Maintenance effect 17.5 mg QW to 15 mg QW to 17.5 mg QW to All Combined observed following Placebo (N=15) 5 mg QOW (N=12) 7.5 mg QOW (N=13) 10 mg QOW (N=12)

  26. Slide 26: Sustained Improvement in Lipids Following Monthly Maintenance Dosing

    Sustained Improvement in Lipids Following 12 Weeks of Monthly Maintenance Dosing Percent Change from Baseline at 34 Weeks (LSM±SE) • Maintenance effect 17.5 mg QW to 17.5 mg QW to 17.5 mg QW to 20 mg QW to 22.5 mg QW to All Combined Placebo 10 mg QM 15 mg QM 17.5 mg QM 20 mg QM 22.5 mg QM QM observe

  27. Slide 27: Discontinuation and GI Tolerability Summary – Induction Phase Through Week 21

    Discontinuation and GI Tolerability Summary – Induction Phase Through Week 21 Dose Level1,2 Placebo VK2735 VK2735 VK2735 VK2735 VK2735 (n=15) Combined 15 mg QW 17.5 mg QW 20 mg QW 22.5 mg QW (n=166) (n=15) (n=121) (n=15) (n=15) Discontinued treatment early 0 (0%) 22 (13%) 2 (13%) 15 (12%) 1 (7%) 4 (

  28. Slide 28: Discontinuation and GI Tolerability Summary – Every Other Week Maintenance Dosing

    Discontinuation and GI Tolerability Summary – Every Other Week Maintenance Dosing Through Week 33 Dose Level1,2 Placebo VK2735 VK2735 VK2735 VK2735 (n=27) Combined QOW 5.0 mg QOW 7.5 mg QOW 10.0 mg QOW (n=37) (n=12) (n=13) (n=12) Discontinued treatment early 0 (0%) 1 (3%) 0 (0%) 0 (0%) 1 (8%) Discon

  29. Slide 29: Discontinuation and GI Tolerability Summary – Monthly Maintenance Dosing

    Discontinuation and GI Tolerability Summary – Monthly Maintenance Dosing Through Week 33 Dose Level1,2 Placebo VK2735 VK2735 VK2735 VK2735 VK2735 VK2735 (n=27) Combined QM 10 mg QM 15 mg QM 17.5 mg QM 20 mg QM 22.5 mg QM (n=66) (n=16) (n=14) (n=11) (n=14) (n=11) Discontinued treatment early 0 (0%) 3

  30. Slide 30: Rates of Common GI-Related AEs, Combined Cohorts

    Rates of Common GI-Related AEs, Combined Cohorts Week 1 to Week 21 Week 21 to Week 33 50% 50% 45% 45% 40% 40% 35% 35% Up titration Up titration Up titration Up titration to 5.0 mg to 10.0 mg to 15.0 mg to 20.0 mg 30% 30% Up titration Up titration Up titration Up titration Up titration QM QoW QM QoW

  31. Slide 31: Rates of Common GI-Related AEs, 17.5 mg Cohort Through W21

    Rates of Common GI-Related AEs, 17.5 mg Cohort Through W21 Up titration to 5.0 mg Up titration Up titration Up titration Up titration Up titration Up titration to 2.5 mg to 7.5 mg to 10.0 mg to 12.5 mg to 15.0 mg to 17.5 mg Reported rates of new GI AEs. Period 1 = Weekly Titration Phase N=121. Titra

  32. Slide 32: VK2735-102 Study Establishes Maintenance Use Case

    VK2735-102 Study Establishes Maintenance Use Case • Rapid Induction with Durable, Tolerable Maintenance Potential Rapid Weight Sustained Weight Loss on Tolerability Potentially Loss Induction Maintenance Dosing Amenable for Long Term Use • Up to ~19% placebo-adj weight loss • Up to ~90% (monthly dos

  33. Slide 33: VK2735 Subcutaneous: VANQUISH Phase 3 Overview

    VK2735 Subcutaneous: VANQUISH Phase 3 Overview • Assess the efficacy & safety of VK2735 SC once weekly for 78 weeks • Enrolled more than 4,500 adults who are obese or overweight with at VANQUISH-1 least one weight-related co-morbid condition • Enrollment completed in 4Q25 Two Phase 3 Studies Ongoing

  34. Slide 34: VANQUISH Phase 3 Study Design

    VANQUISH Phase 3 Study Design Patients 1.25 2.5 5.0 7.5 10.0 12.5 15.0 17.5 with obesity mg mg mg mg mg mg mg mg (VANQUISH-1) 1.25 2.5 5.0 7.5 10.0 12.5 or mg mg mg mg mg mg Extension Patients with study obesity and 1.25 2.5 mg mg 5.0 mg 7.5 mg type 2 diabetes (VANQUISH-2) Placebo 0 2 4 6 8 10 12 14

  35. Slide 35: VK2735 Oral: SUNRISE Phase 3 Overview

    VK2735 Oral: SUNRISE Phase 3 Overview • Assess the efficacy & safety of daily oral VK2735 for 68 weeks • Targeting enrollment of 560 adults who are obese or overweight with at SUNRISE-1 least one weight-related co-morbid condition • Initiated 4Q26 Two Phase 3 Studies Ongoing Data Expected 2028 • Ass

  36. Slide 36: SUNRISE Phase 3 Study Design

    SUNRISE Phase 3 Study Design Patients 10.0 17.5 27.5 35.0 55.0 with obesity mg mg mg mg mg (SUNRISE-1) 10.0 17.5 27.5 35.0 or mg mg mg mg Extension Patients with study 10.0 17.5 27.5 planned obesity and mg mg mg type 2 diabetes (SUNRISE-2) Placebo 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36

  37. Slide 37: VK3019 Amylin Agonist

    VK3019 Amylin Agonist THERAPEUTICS

  38. Slide 38: Amylin Overview

    Amylin Overview • Amylin: Protein secreted by pancreas following nutrient ingestion • Receptors widely expressed in brain • Amylin receptor plays key role in satiety, feeding behavior, glucose control • Receptor activation leads to reduced appetite, body weight, plasma glucose • One approved agent:

  39. Slide 39: Thesis: GLP-1 + Amylin Improves Weight Loss vs. GLP-1 alone

    Thesis: GLP-1 + Amylin Improves Weight Loss vs. GLP-1 alone • Cagrilintide (NVO) is most advanced Change in Body Weight in Obese Subjects Change from baseline (%) long-acting amylin agonist Semaglutide Cagrilintide Cagrisema combo Tirzepatide VK2735 + • Combinations of cagrilintide and 2.4 mg 4.5 mg

  40. Slide 40: Amylin Receptor Binding Summary

    Amylin Receptor Binding Summary Agonist Arrestin Compound hAMY3R (EC50, uM) hCTR (EC50, uM) Selectivity hAMY3 : hCTR • Compounds with balanced activity across amylin 3, calcitonin Calcitonin 0.35 0.03 0.09 receptors desired Pramlintide • VK3012, VK3019 demonstrate 0.002 0.16 80 (Symlin) promise in b

  41. Slide 41: Amylin Agonists: Primate PK Profile Following Single SC Dose

    Amylin Agonists: Primate PK Profile Following Single SC Dose • VK compounds show improved exposures vs NHP Body Weight Change (Single Dose) cagrilintide Change from Baseline (%) • T1/2 suggest weekly dosing feasible 0 • Encouraging BW change observed after single sub-cutaneous doses -5 Tmax Cmax AUC

  42. Slide 42: VK3019 Induces Potent Weight Loss in Obese Primates

    VK3019 Induces Potent Weight Loss in Obese Primates NHP Body Weight Change (Multi-Dose) Change from Baseline (%) • VK3019 demonstrates improved weight loss vs. VK2735 at same dose levels • Rapid trajectory at low doses • Suggests combinations may allow for improved efficacy, tolerability, dose- spar

  43. Slide 43: Amylin Agonists: Primate PK Profile Following Single SC Dose

    Amylin Agonists: Primate PK Profile Following Single SC Dose • Additional amylin leads demonstrate promising T1/2 AUCinf BW Change in-vitro and in vivo profiles Compound (hrs) (h*ng/mL) Day 3, NHP • Similar potency to VK3019 in primates VK3019 86 130,000 -10.0% • T1/2 suggest longer dosing intervals

  44. Slide 44: Amylin Program: Next Steps

    Amylin Program: Next Steps • Phase 1 SAD study of VK3019 nearing completion • Phase 1 MAD planned 2027 • Additional long-acting analog to advance in 2027 44

  45. Slide 45: Summary

    Summary THERAPEUTICS

  46. Slide 46: Advancing Blockbuster Metabolic Pipeline and Preparing for Obesity Commercialization

    Viking Therapeutics: Advancing Blockbuster Metabolic Pipeline and Preparing for Obesity Commercialization • Dual agonist of GLP - 1 and GIP receptors for obesity Lead VK2735 Well-Positioned • Currently in VANQUISH Phase 3 trials in a Blockbuster Market • Potentially 3rd obesity franchise to market O

  47. Slide 47: ObesityWeek 2026

    ObesityWeek 2026

Viking Therapeutics — ObesityWeek 2026 on 6ix